SEC filing record
Primary Source · SEC.gov

Avidity Biosciences, Inc.

2024 vintageSecurities Exchange Act of 1934Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form 15 / Schedule TO; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Latest signalExchange Act deregistrationForm 15-12G · 2026-03-093 events: 1 exchange act deregistration, 1 large raise, 1 new form d filerLast filing 2026-03-09

Raised

$400M

Investors

45

Min Invest

None stated

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

Avidity Biosciences, Inc. is an entity organized in Delaware that first filed a Form D on February 18, 2014 and most recently amended it on March 9, 2026. The offering claims Securities Exchange Act of 1934. Avidity Biosciences, Inc. reported $400,208,765 sold from 45 investors as of the Form D filed March 9, 2026. The Form D names Leerink Partners LLC (CRD 39011), associated with None; BofA Securities Inc. (CRD 283942), associated with None; Cantor Fitzgerald & Co. (CRD 134), associated with None; Chardan Capital Markets, LLC (CRD 120128), associated with None as recipients of sales compensation soliciting in all states. The issuer's address of record is 3020 Callan Road, San Diego, CA 92121.

EDGAR Filing Data

Form 15 / Schedule TO — Primary Source

View on SEC.gov
CIK Number0001599901
Entity NameAvidity Biosciences, Inc.
ExemptionSecurities Exchange Act of 1934
Entity Type—
Jurisdiction of OrganizationDelaware
Issuer Address3020 Callan Road, San Diego, CA 92121
Phone(858) 401-7900
Former NamesAvidity Biosciences LLC (until January 6, 2017); Avidity NanoMedicines LLC (until February 18, 2014)
Industry / Fund Type—
Securities Type—
First Sale Date—
Filing DateMarch 9, 2026
Accession Number0001193125-26-097470
Total Offering Amount$400,208,765
Total Amount Sold$400,208,765
Total Investors45
Minimum Investment$0 (no stated minimum)
Offering Duration—
State (Issuer Address)CA
Amendment Count6 filings on record

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

3

latest Mar 9, 2026

Critical / warning

0 / 3

0 watch · 0 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

3

closed, lapsed

Latest event Exchange act deregistration · Mar 9, 2026

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 3 filing events with values and deltas, latest 2026-03-09, and alerts on the next one
  • 3 offering timelines: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Item 3 changed on the Form D filed 2024-03-19: 7 related persons added and 3 removed against the filing of 2019-11-13; 11 now listed. The names are in the Terminal feed.

Sarah Boyce

Executive Officer, Director · San Diego, CA

Arthur Levin

Executive Officer · San Diego, CA

W. Michael Flanagan

Executive Officer · San Diego, CA

Michael Michael MacLean

Executive Officer · San Diego, CA

Teresa Michael McCarthy

Executive Officer · San Diego, CA

Troy Michael Wilson

Director · San Diego, CA

Carsten Michael Boess

Director · San Diego, CA

Noreen Michael Henig

Director · San Diego, CA

Jean Michael Kim

Director · San Diego, CA

Edward Michael Kaye

Director · San Diego, CA

Tamar Michael Thompson

Director · San Diego, CA

Placement Agents and Sales Compensation (Form D)

Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.

Leerink Partners LLCCRD 39011 on BrokerCheck

Associated broker-dealer: None · Boston, MA · Soliciting in all states

BofA Securities Inc.CRD 283942 on BrokerCheck

Associated broker-dealer: None · Charlotte, NC · Soliciting in all states

Cantor Fitzgerald & Co.CRD 134 on BrokerCheck

Associated broker-dealer: None · New York, NY · Soliciting in all states

Chardan Capital Markets, LLCCRD 120128 on BrokerCheck

Associated broker-dealer: None · New York, NY · Soliciting in AK, AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, IA, ID, IL, IN, KY, MA, MD, MI, MN, NC, ND, NH, NJ, NV, NY, OH, OK, OR, PA, PR, RI, SC, TX, UT, VA, VT, WA, WI

Questions About Avidity Biosciences, Inc.

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is Avidity Biosciences, Inc.?

Avidity Biosciences, Inc. is an issuer that filed a Form D with the SEC on March 9, 2026. The filing claims Securities Exchange Act of 1934.

Is Avidity Biosciences, Inc. legit?

AltStreet does not rate legitimacy; it reports the public record. Avidity Biosciences, Inc. filed a Form D with the SEC on March 9, 2026 claiming Securities Exchange Act of 1934. A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $400,208,765 sold to 45 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is Avidity Biosciences, Inc. registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Avidity Biosciences, Inc. claimed Securities Exchange Act of 1934 and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has Avidity Biosciences, Inc. raised?

Avidity Biosciences, Inc. reported $400,208,765 sold from 45 investors as of the Form D filed March 9, 2026.

Who is selling Avidity Biosciences, Inc. and how are they paid?

The Form D names Leerink Partners LLC (CRD 39011), associated with None; BofA Securities Inc. (CRD 283942), associated with None; Cantor Fitzgerald & Co. (CRD 134), associated with None; Chardan Capital Markets, LLC (CRD 120128), associated with None as recipients of sales compensation soliciting in all states.

Who is behind Avidity Biosciences, Inc.?

The Form D lists 11 related persons: Sarah Boyce, executive officer, director; Arthur Levin, executive officer; W. Michael Flanagan, executive officer; Michael Michael MacLean, executive officer; Teresa Michael McCarthy, executive officer; Troy Michael Wilson, director; Carsten Michael Boess, director; Noreen Michael Henig, director, and 3 more. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is Avidity Biosciences, Inc. located?

The issuer's address on its SEC filings is 3020 Callan Road, San Diego, CA 92121. Its phone number of record is 858-401-7900. It is organized under the laws of Delaware.

How long is the Avidity Biosciences, Inc. offering open?

An issuer must amend its Form D annually while a continuing offering stays open; 1 amendment is on record for this CIK.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.